Pfizer CEO Hank McKinnell will reschedule his Feb. 4 speech at the National Press Club after coming down with the flu. McKinnell was slated to speak on health care reform, but was likely to have also addressed - either through prepared remarks or during the question and answer session - the cardiovascular safety questions surrounding Pfizer's COX-2 inhibitors Celebrex and Bextra (1"The Pink Sheet" Jan. 3, 2005, p. 17). Pfizer says McKinnell caught the flu while traveling through southern Asia to assess the company's tsunami relief effort...
You may also be interested in...
FDA's caution on the use of COX-2 inhibitors leaves open the possibility for patients to use Pfizer's Celebrex and Bextra as first-line therapies
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.